Evaluation of Single Ascending Dose of ZP9830 in Healthy Male Volunteers for Autoimmune Disease Management

The primary objective of this study is to evaluate the safety and tolerability of a single ascending dose of **ZP9830** in healthy male volunteers. This is clinically relevant as it aims to establish the initial safety profile of the investigational product, which is crucial for determining its potential use in treating **autoimmune diseases**. The study does not specify any secondary objectives.

The clinical trial focuses on **autoimmune diseases** and involves a study population consisting exclusively of male participants. The age range of the participants is categorized as adults, specifically between 18 to 65 years old. The trial does not include vulnerable populations, and the selection criteria for the trial population have not been disclosed by the sponsor. Additionally, the sponsor has not provided information regarding the total number of participants involved in the study. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits that may be relevant to the study. Key inclusion or exclusion criteria have not been detailed in the available data.

The clinical trial is designed to evaluate the safety and tolerability of a **single ascending dose** of ZP9830 in healthy male volunteers. This study is a **Phase 1** trial, focusing on the initial assessment of the investigational product in humans. The trial employs a **randomized, double-blind, controlled** design to ensure unbiased results and to maintain the integrity of the data collected. The estimated recruitment start date is October 28, 2024, with the trial expected to conclude by December 1, 2025, indicating an overall duration of approximately 13 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion. Following successful screening, participants will be randomized and receive the investigational product. Subsequent follow-up visits will be scheduled to monitor safety, collect pharmacokinetic data, and assess any adverse events. These visits are critical for evaluating the primary and secondary endpoints of the study. The end-of-study visit will mark the completion of the participant's involvement, where final assessments will be conducted to gather conclusive data on the investigational product's safety profile.

The expected length of participant involvement is contingent upon the dosing schedule and follow-up period, typically spanning several weeks to months, depending on the specific protocol requirements. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines and regulatory standards to ensure participant safety and data integrity throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of this information suggests that the trial may focus solely on the experimental medication, but further details would be necessary to confirm this aspect of the study design.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is October 28, 2024, with an anticipated end date of December 1, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant biomarkers or symptom improvement. The schedule for measuring and collecting data is typically aligned with the trial's timeline, ensuring systematic data collection at predefined intervals. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product. The trial's design and methodology adhere to regulatory standards to ensure the reliability and validity of the findings.